GRAIL Quote - GRAL

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

14.40

Bid

10.07

Ask

15.89

Volume

873,046

13.5401 Day's Range 14.43

12.56 52 Week Range 21.47

Market Cap

447.108M

Previous Close

13.60

Open

13.70

Last Trade

14.35

Last Trade Time

Financial Volume

US$ 12,363,740

VWAP

14.1616

Average Volume (3m)

1,084,841

Shares Outstanding

31,049,148

Dividend Yield

PE Ratio

-0.30

Earnings Per Share (EPS)

-47.21

Revenue

93.11M

Net Profit

-1.47B

GRAIL is a healthcare company innovating to solve medicine's most important challenges. The Company's team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it may be more treatable and potentially curable. GRAIL is a healthcare company innovating to solve medicine's most important challenges. The Company's team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it may be more treatable and potentially curable.

Sector

Medical Laboratories

Industry

Medical Laboratories

Website

grail.com

Headquarters

Wilmington, Delaware, USA

Founded

GRAIL Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker GRAL. The last closing price for GRAIL was US$13.60. Over the last year, GRAIL shares have traded in a share price range of US$ 12.56 to US$ 21.47.

GRAIL currently has 31,049,148 shares outstanding. The market capitalization of GRAIL is US$422.27 million. GRAIL has a price to earnings ratio (PE ratio) of -0.30.

Nvidia Subpoenaed by DOJ, Athira Pharma Shares Plunge 71% After Study Fails, Zscaler Falls 15% Post-Earnings

Nvidia (NASDAQ:NVDA) – Nvidia’s stock closed down 9.5% on Tuesday, leading to a $279 billion loss in market value due to fading optimism over AI following weak economic data...

GRAIL ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4)

GRAIL ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4) PR Newswire MENLO PARK, Calif., Aug. 30, 2024 MENLO PARK, Calif., Aug. 30, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL...

Results of GRAIL's Galleri® Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology

Results of GRAIL's Galleri® Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology PR Newswire MENLO PARK, Calif., Aug. 29, 2024 Data Support Clinical...

GRAIL to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

GRAIL to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference PR Newswire MENLO PARK, Calif., Aug. 21, 2024 MENLO PARK, Calif., Aug. 21, 2024 /PRNewswire/ -- GRAIL, Inc...

GRAIL Reports Second Quarter 2024 Financial Results and Provides a Strategic Update

GRAIL Reports Second Quarter 2024 Financial Results and Provides a Strategic Update PR Newswire MENLO PARK, Calif., Aug. 13, 2024 Second Quarter Revenue Grew 43% Year-Over-Year to $32.0...

Wheels Up Announces Gregory Summe to Join Board of Directors

Wheels Up Announces Gregory Summe to Join Board of Directors PR Newswire ATLANTA, Aug. 8, 2024 Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug...

GRAIL to Announce Second Quarter 2024 Financial Results

GRAIL to Announce Second Quarter 2024 Financial Results PR Newswire MENLO PARK, Calif., July 31, 2024 MENLO PARK, Calif., July 31, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare...

GRAIL Announces First Participant Enrolled in REACH Study Evaluating Clinical Impact of Galleri® Multi-Cancer Early Detection (MCED) Test in the Medicare Population

GRAIL Announces First Participant Enrolled in REACH Study Evaluating Clinical Impact of Galleri® Multi-Cancer Early Detection (MCED) Test in the Medicare Population PR Newswire MENLO PARK...

GRAIL Advances the Galleri® Registrational Clinical Trial Program

GRAIL Advances the Galleri® Registrational Clinical Trial Program PR Newswire MENLO PARK, Calif., July 15, 2024 GRAIL Completes Enrollment of More Than 35,000 Participants in the PATHFINDER 2...

Nike Stock Drops 14% in Pre-Market; Nokia Acquires Infinera for $2.3 Billion, and More News

Nike (NYSE:NKE) – Nike shares fell 14.04% in pre-market trading. Nike exceeded fourth-quarter fiscal earnings estimates with adjusted earnings of $1.01 per share, but sales of $12.6 billion...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.53	3.82119682769	13.87	14.4	12.56	1098984	13.42929982	CS
4	-0.54	-3.61445783133	14.94	14.94	12.56	1067136	13.55262047	CS
12	-1.07	-6.91661279897	15.47	21.47	12.56	1084841	15.4068083	CS
26	-4.23	-22.7053140097	18.63	21.47	12.56	1430877	15.62401655	CS
52	-4.23	-22.7053140097	18.63	21.47	12.56	1430877	15.62401655	CS
156	-4.23	-22.7053140097	18.63	21.47	12.56	1430877	15.62401655	CS
260	-4.23	-22.7053140097	18.63	21.47	12.56	1430877	15.62401655	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
UXINUxin Ltd	US$ 5.145 (81.80%)	46.69M
ONCOOnconetix Inc	US$ 5.92 (76.43%)	34.68M
JFU9F Inc	US$ 2.3101 (76.34%)	2.48M
NANano Labs Ltd	US$ 1.005 (73.31%)	3.34M
CNEYCN Energy Group Inc	US$ 0.9473 (63.36%)	221.89M
ICGIntchains Group Ltd	US$ 4.77 (-43.75%)	2.86M
EDBLEdible Garden AG Inc	US$ 0.288 (-38.09%)	5.79M
DSYBig Tree Cloud Holdings Limited	US$ 2.44 (-28.24%)	416.35k
NVNOenVVeno Medical Corporation	US$ 3.255 (-27.67%)	2.36M
ADTXAditxt Inc	US$ 0.165 (-24.83%)	12.23M
NVDANVIDIA Corporation	US$ 121.40 (-2.13%)	271.06M
XPONExpion360 Inc	US$ 0.0717 (11.34%)	266.01M
CNEYCN Energy Group Inc	US$ 0.9473 (63.36%)	221.89M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.1462 (7.03%)	207.04M
SQQQProShares UltraPro Short QQQ	US$ 7.45 (1.78%)	133.67M